沙库巴曲缬沙坦钠片治疗冠心病合并慢性心力衰竭的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (549 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of Sacubitril Valsartan Sodium Tablets in the treatment of coronary heart disease complicated with chronic heart failure (CHF) and the effect on the level of N-terminal pro-Btype natriuretic peptide (NT-proBNP) and cardiac function in patients. Methods A total of 126 patients with coronary heart disease and CHF admitted to Longkou People′s Hospital from January 2018 to January 2020 were selected as the research subjects. According to random number table method，they were divided into control group and observation group，63 cases in each group. The control group was treated with conventional treatment，and the observation group was treated with Sacubitril Valsartan Sodium Tablets on the basis of the control group，and continued to take medicine for 3 months. Clinical efficacy，NT-proBNP level，cardiac function indexes (left ventricular ejection fraction [LVEF]，stroke output [SV]，cardiac output [CO])，6-min walking distance，quality of life and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was higher than control group，the difference was statistically significant (P＜0.05). There was no significant difference in NT-proBNP level and cardiac function indexes between the two groups before treatment (P＞0.05). The level of NT-proBNP after treatment was lower than before treatment，while LVEF，SV and CO were higher than before treatment，the differences were statistically significant (P＜0.05). After treatment，the level of NT-proBNP in the observation group was lower than that in the control group，while LVEF，SV and CO were higher than those in the control group，the differences were statistically significant (P＜0.05). There were no significant differences in walking distance and Minnesota heart failure quality of life scale (MLHFQ) score before treatment between the two groups (P＞0.05). The walking distance 6 min after treatment was longer than before treatment，and the MLHFQ score was lower than before treatment，the differences were statistically significant (P＜0.05). The observation group had longer walking distance 6 min after treatment than the control group，and the MLHFQ score was lower than the control group，the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Sacubitril Valsartan Sodium Tablets can enhance the therapeutic effect of coronary heart disease complicated with CHF，reduce the serum NT-proBNP level，accelerate the recovery of cardiac function，improve the quality of life of patients，and it is safe and reliable.

Key words： Coronary heart disease Chronic heart failure Sacubitril Valsartan Sodium Tablets Cardiac function Safety

Received: 20 August 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2022/V29/I1/68

[1]	宁靓，李洪卫，赵天华，等.依那普利片联合乌拉地尔注射液治疗冠心病合并心力衰竭的临床研究[J].中国临床药理学杂志，2019，35（18）：1979-1981.
[2]	王毅，杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志，2019，48（4）：470-472.
[3]	董蕾，田颖，刘肆仁，等.沙库巴曲缬沙坦钠片对慢性心力衰竭患者的疗效及对神经内分泌激素活性的影响[J].中国医药，2019，14（5）：655-658.
[4]	闫贤良，高玉龙，陶英，等.沙库巴曲缬沙坦钠在心力衰竭患者中的临床疗效观察[J].中国循证心血管医学杂志，2019，11（10）：1248-1250，1254.
[5]	戴聪，杨人强，邹凯，等.沙库巴曲缬沙坦在心力衰竭患者临床应用中的观察[J].临床心血管病杂志，2019，35（7）：661-664.
[6]	戴颐.沙库巴曲缬沙坦钠联合环磷腺苷葡胺治疗舒张性心力衰竭的临床研究[J].现代药物与临床，2020，35（11）：2233-2237.
[7]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[8]	王贤良，刘洪伟，毛静远，等.基于中国文化改良明尼苏达心力衰竭生存质量量表的测评[J].中国中西医结合杂志，2016，36（9）：1072-1075.
[9]	刘美林，高宇勤，张一凡，等.沙库巴曲缬沙坦联合托伐普坦治疗慢性心力衰竭的疗效观察[J].检验医学与临床，2020，17（21）：3144-3147.
[10]	程明月，张辉，徐晤，等.沙库巴曲缬沙坦联合呋塞米治疗慢性心力衰竭的疗效研究[J].现代生物医学进展，2019，19（22）：4295-4298.
[11]	黄馨，黄银花，吴志坚.沙库巴曲缬沙坦治疗慢性心力衰竭患者的临床疗效研究[J].中国循证心血管医学杂志，2020，12（1）：100-102，106.
[12]	赵晓琴.沙库巴曲缬沙坦治疗难治性心力衰竭的临床研究[J].现代药物与临床，2020，35（6）：1146-1150.
[13]	李斐，胡骏，冯启凡.米力农联合多巴胺对慢性心力衰竭的疗效及对血清CysC NT-proBNP IL-6 的影响[J].河北医学，2019，25（8）：1329-1333.
[14]	徐亮，杨松，王稳，等.NT-proBNP 对慢性心力衰竭患者心功能的评估价值[J].临床和实验医学杂志，2018，17（24）：2626-2629.
[15]	章体玲，张伟华，罗庆祎，等.沙库巴曲缬沙坦治疗扩张型心肌病心力衰竭的疗效[J].昆明医科大学学报，2020，41（3）：91-95.
[16]	杨昌林.沙库巴曲缬沙坦钠片治疗高龄慢性心力衰竭效果观察[J].人民军医，2019，62（9）：847-849，855.